These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

92 related items for PubMed ID: 4195149

  • 1. L-dopa in progressive supranuclear palsy.
    Dehaene I, Bogaerts M.
    Lancet; 1970 Aug 29; 2(7670):470. PubMed ID: 4195149
    [No Abstract] [Full Text] [Related]

  • 2. L-dopa for progressive supranuclear palsy.
    De Renzi E, Vignolo LA.
    Lancet; 1969 Dec 20; 2(7634):1360. PubMed ID: 4188119
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Progressive supranuclear palsy.
    Steele JC.
    Brain; 1972 Dec 20; 95(4):693-704. PubMed ID: 4647151
    [No Abstract] [Full Text] [Related]

  • 6. The treatment of progressive supranuclear palsy with L-dopa.
    Donaldson IM.
    Aust N Z J Med; 1973 Aug 20; 3(4):413-6. PubMed ID: 4519129
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. L-dopa for progressive supranuclear palsy.
    Jenkins R.
    Lancet; 1969 Oct 04; 2(7623):742. PubMed ID: 4186183
    [No Abstract] [Full Text] [Related]

  • 9. Observations on the range of efficacy of L-dopa.
    Klawans HL.
    Confin Neurol; 1971 Oct 04; 33(3):133-45. PubMed ID: 4940610
    [No Abstract] [Full Text] [Related]

  • 10. Observations on the efficacy of L-dopa in progressive supranuclear palsy.
    Klawans HL, Ringel SP.
    Eur Neurol; 1971 Oct 04; 5(2):115-29. PubMed ID: 5117103
    [No Abstract] [Full Text] [Related]

  • 11. [Progressive supranuclear paralysis. Critical review, with a note on verbal expression disorders and action of L-dopa].
    Giménez-Roldán S, Esteban A.
    Arch Neurobiol (Madr); 1972 Oct 04; 35(1):41-60. PubMed ID: 5060240
    [No Abstract] [Full Text] [Related]

  • 12. [Improvement of ophthalmoplegia by 5-hydroxytryptophan in two cases of progressive supranuclear palsy].
    Yukitake M, Takashima Y, Kurohara K, Matsui M, Kuroda Y.
    Rinsho Shinkeigaku; 1996 Jul 04; 36(7):906-8. PubMed ID: 8952364
    [Abstract] [Full Text] [Related]

  • 13. Progressive supranuclear palsy (the Steele-Richardson-Olszewski syndrome) clinical and electrophysiological observations in eleven cases.
    Mastaglia FL, Grainger K, Kee F, Sadka M, Lefroy R.
    Proc Aust Assoc Neurol; 1973 Jul 04; 10(0):35-44. PubMed ID: 4792160
    [No Abstract] [Full Text] [Related]

  • 14. L-dopa for progressive suparanulcear palsy.
    Sacks OW.
    Lancet; 1969 Sep 13; 2(7620):591-2. PubMed ID: 4185547
    [No Abstract] [Full Text] [Related]

  • 15. Neurofibrillary tangles in progressive supranuclear palsy. Electron microscopic observations.
    Powell HC, London GW, Lampert PW.
    J Neuropathol Exp Neurol; 1974 Jan 13; 33(1):98-106. PubMed ID: 4812327
    [No Abstract] [Full Text] [Related]

  • 16. L-dopa and amantadine hydrochloride in extra-pyramidal disorders.
    Parkes JD, Knill-Jones RP, Clements PJ.
    Postgrad Med J; 1971 Feb 13; 47(544):116-9. PubMed ID: 5572526
    [Abstract] [Full Text] [Related]

  • 17. Modification by L-dopa of a case of progressive supranuclear palsy. With evidence of defective cerebral dopamine metabolism.
    Mendell JR, Engel WK, Chase TN.
    Lancet; 1970 Mar 21; 1(7647):593-4. PubMed ID: 4190545
    [No Abstract] [Full Text] [Related]

  • 18. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
    Brooks DJ, Ibanez V, Sawle GV, Quinn N, Lees AJ, Mathias CJ, Bannister R, Marsden CD, Frackowiak RS.
    Ann Neurol; 1990 Oct 21; 28(4):547-55. PubMed ID: 2132742
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.